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1INTRODUCTION 
 
The use of cyclodextrins (CDs) for the solubilization, stabilization and formulation of 
drugs through the formation of inclusion complexes, while summarized findings on the safety 
profile of CDs. Numerous other major reviews have been published on the current and 
potential uses of CDs. Many new, and many more old, generic drugs need appropriate 
formulation, better than what was considered satisfactory some years ago. The search for new 
drugs (which exponentially rising expense) continues, but the search for new formulations 
(witch are less expensive) resulting in more stable preparations with better bioavailability 
properties, allowing the design of new, and more effective drug delivery systems, is 
increasing more rapidly. This provides the main impetus for the research into CD-drug 
combinations. Investigations into bioavailability increase comprise one of the dynamically 
developing fields of drug research. While studies on the bioavailability of drugs from a given 
dosage form have revealed that in many situations various dosage forms with the same 
content of active substance did not give the same therapeutic effect control of the 
bioavailability of drugs is a major requirement in drug production, especially for drugs of 
very low water solubility. This work is based on the investigation of gemfibrozil (GEM), 
which has a lipid-regulating pharmaceutical effect, and its solubility properties, with a view to 
improving the bioavailability of GEM, and therefore decreasing its dose and side effects. 
The main line of my experiments is in vitro availability studies, and some other 
examinations suitable for the evaluation of complex formation. In several cases, I have 
formulated complete solid dosage forms (tablets and capsules), where the in vitro availability 
is better than that of the official dosage forms. 
 
OBJECTIVES 
 
The investigation of the following phenomena were the objectives of my Ph.D. research: 
• Investigation of the solubility increasing effect of different CD-derivatives and 
selection of the proper complex forming agent of GEM + dimethyl-.-cyclodextrin 
(DIMEB); 
• Preparation of products with selected CD-derivatives (DIMEB) in different ratios 
and methods of preparation; 
• Determination of the products (inclusion complexes) of the following studies: 
o Phase solubility diagram, 
o Solubilty and dissolution rate, 
2o In vitro membrane diffusion kinetics, 
o n-octanol/water partition coefficient, 
o Thermoanalytical investigations (TG, DTG, DTA, and DSC), 
o FT-IR, 1H NMR, and X-ray powder diffraction investigations; 
• Powder technological investigations: 
o Partical size distribution, 
o SEM investigation of the complex surface, 
o Contect wetting angles determination; 
• Preparation of solid dosage forms from 1:2 GEM + DIMEB kneaded product 
(capsules and tablets); 
• Examinations of capsules and tablets. 
MATERIALS AND METHODS 
 
Gemfibrozil is 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid (Fig. 1), (Plantex Chemicals, 
Israel, API Division Teva Group). 
 
Fig. 1. Chemical structure of GEM 
 
Description: the empirical formula is C15H22O3 and the molecular weight is 250.35. The 
solubility in water and acid is 0.0019 % and in dilute base it is greater than 1%. The melting 
point is 58–61°C. GEM is a white waxy crystalline solid powder, which is stable under 
ordinary conditions. It is a lipid-regulating agent. It is available as tablets (LOPID®,
INNOGEM®, MINILIP®) for oral administration. Each tablet contains 300 or 600 mg GEM. 
Cyclodextrins: E-CD, .-CD, F-CD, hydroxybutenyl-.-CD (HBU-.-CD), 2-hydroxypropyl-
.-CD (HP-.-CD), heptakis-2,6-di-O-methyl-.-CD (DIMEB), and randomly methylated-.-CD 
(RAMEB) (Cyclolab R&D Laboratory Ltd., Hungary); Captisol® (Cydex, Inc., USA). 
Other materials: Microcrystalline cellulose (Avicel PH 101) (FMC Corp., USA), lactose, 
magnesium stearate and talc (Ph. Eur. 4th); sodium starch glycolate (VIVASTAR®) (J. 
Rettenmaier and Söhne GmbH, Germany); silicified microcrystalline cellulose (Prosolv 
SMCCTM 50) (England), n-octanol (Molar Chemicals Kft., Hungary), disodium-hydrogen-
COOHO C(CH2)3 (CH3)2
CH3
CH3
3phosphate, potassium dihydrogenphosphate, sodium chloride, glycine, and hydrochloric acid 
(Reanal Co., Hungary). 
 
Methods 
Preparation of products 
Products were prepared in four different molar ratios (GEM+CD molar ratio = 2:1, 1:1, 
1:2 and 1:3). Physical mixtures (PMs): the pure drug and CD were mixed in a mortar and 
sieved through a 100 µm sieve. Kneaded products (KPs): PMs of the drug and DIMEB were 
mixed (Erweka LK5) with the same quantity of a solvent mixture of ethanol + water (1:1). 
They were kneaded until the bulk of the solvent mixture had evaporated. After this they were 
dried at room temperature and were then pulverized and sieved through a 100 µm sieve. 
Spray-dried products (SDs): the PMs of GEM and DIMEB were dissolved in 50% ethanol. 
The SDs were obtained by using a Büchi Mini Dryer B-191, with compressed air flow: 800 
L/min at 75 °C inlet temperature, and nozzle diameter: 0.5 mm. The aspirator rate was 75–
80%, and the pump rate was 3–7%. Products prepared by ultrasound treatment (USs): GEM 
and DIMEB with different molar ratios of PMs were dissolved in 50% ethanol and mixed to 
obtain clear solutions, then placed in the ultrasound apparatus for 1 h, dried at room 
temperature, pulverized and sieved through a 100 µm sieve. 
Products were stored under normal conditions at room temperature in well-closed glass 
containers. 
 
Preparation of solid dosage forms  
The powder components (except the magnesium stearate) were measured and mixed for 8 
min (50 rpm) in a Turbula mixer (WAB Turbula, Switzerland). Homogenization was repeated 
after the addition of magnesium stearate (2 min). The moisture contents of the GEM+DIMEB 
1:2 KP and the homogeneous PM were determined in 3 parallel measurement (Mettler Toledo 
HR 73 Halogen Moisture Analyzer, Mettler-Toledo GmbH, Switzerland). 
Tabletting was carried out with a Korsch EK 0 eccentric tablet machine (E. Korsch 
Maschinenfabrik, Germany). 
The hard gelatin capsules were prepared with the ZUMA semiautomatic capsule-filling 
machine (150 A/4 with 150/B-3, Zuma S.r.L., Italy). Prosolv SMCCTM 50 with good 
flowability was used as filler. The calculated quantities of the components were measured and 
homogenized with a Turbula mixer for 10 min. The capsules were white 
4hydroxypropylmethyl cellulose (HPMC) hard ones (size 2) (Syntapharma, GES für 
Pharmachemie mbH). The dissolution and in vitro membrane diffusion results of the 1:2 
product gave the basis for the determination of the active agent content. Tablets and capsules 
containing 8.84 mg active agent were prepared. Literature data from previous studies, book, 
etc. were used when the auxiliary materials were selected for tabletting and also in the choice 
of the tabletting methodology, the composition of the tablets and capsules are presented in the 
following table: 
 
Table 1. Compositions of tablets and hard gelatin capsules 
Components Tablet Capsule 
mg % mg % 
1:2 KP (GEM + DIMEB) 89.50 49.73 89.50 50.04 
Avicel PH 101 54.00 30.00 –  
Lactose 30.20 16.77 –  
Talc 3.60 2.00 –  
Vivastar 1.80 1.00 –  
Magnesium stearate 0.90 0.50 –  
Prosolv SMCCTM 50 – – 88.08 49.96 
Average mass 180.00 100.00 177.58 100.00 
RESULTS AND DISCUSSION 
 
The aim of this work was to assess the ability of DIMEB to form inclusion compounds of 
gemfibrozil. This will permit establishment of the best vehicle for GEM preformulation in 
order to enhance its solubility and bioavailability, the possibility, that the molecule size and 
the structure allow the material to form inclusion complex with CDs, and promising a 
decrease in the therapeutic dose. 
My work can be summarized as following: 
 
In vitro availability investigation result 
Solubility increasing effect of the available CD derivatives was determined in uniform 
conditions. It was established, that the solubility of the active ingredients were always higher 
with CDs (expect the GEM and DIMEB). Fig. 2. show phase solubility equilibrium diagram 
for the GEM + DIMEB system in water 25 oC. The solubility of GEM increased linearly in 
5the presence of this CD derivatives (see Table 2). The variable of the solubility increasing 
values were high enough (2.5 mg/100ml to 65.5 mg/100ml increased the solubility). 
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In the past few decades, the pharmaceutical modification of drug molecules by 
inclusion complexation has been extensively developed to improve their dissolution rate, 
chemical stability, absorption and bioavailability. In this respect, cyclodextrins have received 
an increasing attention in the pharmaceutical field, and there is no doubt that the 
determination of dissolution rates is an important tool in the development, evaluation, and 
control of solid dosage forms. The DIMEB showed the highest solubility-increasing effect on 
the solubility of GEM (see Table 2.), were the dissolution of the products was better than that 
of the pure drug, the dissolution rate depended on the CD content. The GEM dissolves 
sparingly in SGM: only 2.6 mg /100 mL dissolved during the 2 h investigation period. The 
solubility is better in SIM, as a result of its chemical nature: 38.0 mg dissolves in 100 mL 
acceptor phase in 2 h. The dissolution of the CD-containing products was in all cases better 
than that of the pure drug. A 3–6-fold solubility increase was measured depending on the 
preparation methodology (e.g. see Fig. 3 and 4). 
 
Fig. 2. Diagram of 
increasing solubility of 
GEM+CD-derivatives in 
water at 25 oC
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Fig. 3. Dissolution of GEM and SDs in SGM             Fig. 4. Dissolution of GEM and USs in SGM   
 
Table 2. Influence of CD derivatives on the solubility of GEM 
Components C (µg/mL) Increasing (fold) 
GEM 29.10 1.00 
GEM + E-CD 31.39 1.08 
GEM + .-CD 49.62 1.71 
GEM + F-CD 253.44 8.71 
GEM + HP-.-CD 212.71 7.31 
GEM + HBU-.-CD 284.84 9.79 
GEM + RAMEB 330.63 11.33 
GEM + DIMEB 655.44 22.53 
GEM + Captisol® 251.91 8.66 
Some of the products dissolved totally in the small volume of acceptor phase, in spite of 
the increased GEM content of the product. Therefore, the saturation concentration was 
determined for all of the products. The results for the SDs as an example (see Fig. 5). 
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Fig. 5. Dissolution of GEM and SDs in SIM 
7The in-vitro membrane-diffusion 3–5-fold increased from SGM, whereas from SIM was 
to the same extent (see Fig. 6, 7). The amount diffused of drug through the membrane into 
simulated plasma medium during 150 min under in vitro conditions, was not dependent on the 
composition of the products or on the preparation method used. The highest diffunded active 
material quantity and the diffusion constant were found to be 3–4 times higher than in case of 
the pure GEM. The significant differences in the values of the diffusion rate were constant. 
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Fig. 6. In vitro membrane diffusion                    Fig. 7. In vitro membrane diffusion  
 results on SDs in SGM                                         result on SDs in SIM 
 
Therefore, the linear part (between 30 and 90 min) of the curves was used to calculate the 
diffusion rate constants (Kd), where (1:2 and 1:3) ratio were recorded higher amount diffusion 
of GEM with DIMEB comparing with the original drug. On the basis of the dissolution and 
membrane diffusion results, the active agent content and the degree of solubility increase, I 
selected 1:2 kneaded products, which were incorporated in solid dosage forms (tablets and 
capsules). 
 
Thermoanalytical, FT-IR, X-ray and 1H NMR results 
1. The DSC examinations demonstrated a phase transitions more or less in all 
complexes of different preparative methods, showing an exo/endo peaks related to a 
crystalline/amorphous transition with different amount of adsorbed water. 
2. The X-ray powder diffraction data can explain the nature of the host-guest 
interactions in crystalline CD inclusion compounds. The changes in the powder 
crystallinity of the samples were studied by comparing their diffraction patterns. The 
peaks relating to the crystalline GEM are to be found in the X-ray diffractogram, with 
8lower intensities as compared with those of GEM itself, in accordance with the active 
agent content of the product. 
3. The findings from the FT-IR spectra confirmed the existence of intermolecular 
bonding between GEM and the hosts, with significant shifts of the absorption band 
lines. The different ratios used in the complexes formation greatly influenced the 
solubility of GEM.  
4. True inclusion complex formation was confirmed by 1HNMR investigation. It was 
established that there were chemical bonds between the aromatic ring part (the most 
non-polar part) incorporated in the cavity of the CD molecule. The methyl protons 
from the long side-chain and the aromatic proton para to the side-chain are mostly 
incorporated into the CD. 
 
Powder technological characterization studies 
Evaluation of the rheological behavior of GEM + DIMEB powders was of great 
importance, particularly that needed for tablets or capsules production, and it was also 
necessary to determine the preliminary compression behavior of the complex affording the 
best results GEM + DIMEB as preformulated product in new tablets or capsules preparations 
of GEM. 
 
Particle size analysis and wetting angle results 
The powder characterization on the particles size analysis were determined the particles 
were mainly spherical; their size varied in only a narrow range; the average size was 2–4 Sm; 
the number of bigger particles was extremely low. 
Significantly lower wetting angles were measured for the DIMEB-containing products as 
compared with the pure GEM. These results were affected by changes of the composition, and 
also the preparation methods (see Table 3). 
 
Table 3. Wetting angles of GEM and its products  
(at 5 s) 
2:1 1:1 1:2 1:3 
° Std. ° Std. ° Std. ° Std. 
PM 27.6 ±2.2 41.5 ±2.2 42.5 ±3.7 39.9 ±4.8
KP 16.5 ±3.3 24.3 ±4.5 38.9 ±1.2 29.6 ±0.9
US 44.8 ±7.6 25.0 ±1.6 35.6 ±1.7 32.0 ±1.3
GEM 64.8 ±0.2
9Morphological study 
SEM (scanning electron microscope) investigated the morphological properties of the 
pure GEM, DIMEB and SDs, where the GEM (Fig. 8/a) consists of crystals with mainly a 
columnar form and a broad size distribution. The edges of the columnar crystals are rounded. 
The surface of these crystals is generally smooth, but in some places small particles can be 
seen on it. Therefore, such small crystals occur among the larger crystals. The picture of 
DIMEB (Fig. 8/b) demonstrates a product with heterodisperse particles. The product consists 
of irregularly shaped, differently sized particles. The spray-drying method is a good one for 
preparing products with better rheological properties (Fig. 8/c, SDs 1:1). These products have 
small is dimensional particles, which is important in the formulation of solid dosage forms. 
The particle size is different, but its surface is smooth. 
 
8/a                                       8/b                                        8/c                      
Fig. 8. SEM photograph of GEM (a), DIMEB (b) and SD 1:1 product (c) 
 
Tablet and capsule test result 
Results of the tablet and capsule tests are shown in Table 4. 
 
Table 4. Physical parameters of tablets and capsules (result and standard 
deviation)
Examinations Tablet Capsule 
Average mass (mg) 177.24 227.22 
Uniformity of mass (mg) ±4.3 ±4.5
Height (mm) 3.172 Std. 0.019 – 
Diameter (mm) 9.074 Std. 0.024 – 
Friability (%) 0.258 Std. 0.035 – 
Breaking hardness (N) 49.0 Std. 6.782 – 
Disintegration time (s) in SGM 220.72 78.58 165.66 37.68 
Disintegration time (s) in SIM 199.17 53.02 143.33 61.02 
10
Dissolution profiles of tablets and capsules 
To summarize the dissolution data, we found that the active agent was released relatively 
quickly, and the dissolution profile from the solid dosage forms depended only slightly on the 
pH of the acceptor medium (see Fig. 9, 10). 
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Fig. 9. Profile of GEM dissolution from tablets                Fig. 10. Profile of GEM dissolution from 
 capsules 
 
Membrane diffusion of tablets and capsules 
The in vitro membrane diffusion ability of solid dosage forms from SGM and SIM was 
measured (Fig. 11 and 12). 
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11
Less drug diffused through the artificial membrane in the case of SGM (tablets: 23% after 
150 min; capsules: more than 17%). 38–41% GEM content was measured in the acceptor 
phase in the case of SIM. A higher standard deviation was experienced for the capsule dosage 
form. 
 
SUMMARY 
To summarize the results, it may be conclude that the inclusion complexes formed 
between GEM and CD derivatives as hosts are of promise as for better future 
pharmaceuticals. Through their use, there is a possibility to improve the bioavailability of 
poorly water-soluble drugs, which is important as regards their industrial price, and promising 
as concerns decrease of the therapeutic dose of the given drug. 
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